ArticleCancers2019
A Pilot Clinical Study on the Prognostic Relevance of Plasmatic Exosomes Levels in Oral Squamous Cell Carcinoma Patients.
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.
- Extracellular Vesicles in Oral Squamous Cell Carcinoma and Oral Potentially Malignant Disorders: A Systematic Review.International journal of molecular sciences · 2020Pooled it
- Development and validation of a noninvasive machine learning model using urinary extracellular vesicle physical parameters for prostate cancer diagnosis.Scientific reports · 2026Article
- Review
- Extracellular vesicles as prognostic biomarkers: results of a neoadjuvant chemoimmunotherapy clinical trial in stage IIIA (N2) non-small-cell lung cancer (SAKK 16/14).Frontiers in immunology · 2026Article
- Proteomic analysis of altered urinary extracellular vesicle levels in breast cancer patients pre- and post-surgery.Translational cancer research · 2025Article
- Role of exosomes in cancer: from diagnosis to therapy.Discover oncology · 2025Review
- hsa-miR-144-3p and hsa-miR-4262 are exosomal biomarkers and function as tumor suppressors in HCMV positive brain tumor.Future oncology (London, England) · 2025Observational
- Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives.European journal of medical research · 2025Review
- Tumor-derived exosomes and their application in cancer treatment.Journal of translational medicine · 2025Review
- Exosomal Biomarkers: A Comprehensive Overview of Diagnostic and Prognostic Applications in Malignant and Non-Malignant Disorders.Biomolecules · 2025Review
- A single-sEV analysis identifies plasma EPCAMExtracellular vesicles and circulating nucleic acids · 2025Article
- Role of Exosomes in Salivary Gland Tumors and Technological Advances in Their Assessment.Cancers · 2024Review
- Extracellular vesicles promote migration despite BRAF inhibitor treatment in malignant melanoma cells.Cell communication and signaling : CCS · 2024Article
- Review
- The Diagnostic and Prognostic Value of Plasmatic Exosome Count in Cancer Patients and in Patients with Other Pathologies.International journal of molecular sciences · 2024Article
- Exosomes in Cancer: Diagnostic and Therapeutic Applications.Clinical Medicine Insights. Oncology · 2024Review
- Article
- MicroRNA Profiling in Circulating Exosomes in Oral Squamous Cell Carcinoma: A Systematic Review.Cureus · 2023Review
- Review
- Plasma‑derived CD16 exosomes and peripheral blood monocytes as correlating biomarkers in head and neck cancer.Oncology letters · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the relationship between the plasmatic CD63 and CAV1 positive exosome levels, in patients with OSCC before and after surgical treatment and to correlate it with their overall survival.
methodsA double-blind pilot study over 10 patients OSCC and T4 stage without distant metastases or local bone invasion has been performed. The average follow-up period was 37.64 months (34.3⁻40.84). We obtained 2 plasma tubes of 1 mL each before surgery and 7 days after surgery. Before performing the immunocapture-based analysis, EVs (Extracellular Vesicles) were isolated from the plasma and characterized with western blot analysis.
resultsMean values of CD63 positive plasmatic exosomes (EXO-CD63) after surgery decreased from 750.88 ± 286.67 to 541.71 ± 244.93 (
conclusionsSurgical treatment induced a dramatic reduction of the plasmatic levels of exosomes expressing CD63 as early as 1 week after resection. This first result suggests that the tumour mass is responsible of the high levels of circulating exosomes detected in cancer patients. At the same time point exosome expressing CAV-1 increased, possibly due to the inflammatory reaction immediately after surgery. Lastly, statistical analysis showed that lower levels of plasmatic exosomes both before and after surgery correlated with a better life expectancy of OSCC patients. Hopefully, this approach will prove useful in the clinical follow-up of cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.